First Orexin Receptor Antagonist Approved for Insomnia

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 114, Nº. 12, 2014, págs. 26-26
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Suvorexant (Belsomra) is the first orexin receptor antagonist to be approved for the treatment of insomnia.

    * The most common adverse effect is daytime somnolence. The performance of complex activities during sleep, such as driving, having sex, making phone calls, or eating, is possible and is more likely when a dose of more than 10 mg is taken.

    * Patients should be warned not to drive or operate heavy machinery the morning after taking suvorexant until it's clear whether it causes daytime sedation.